Oral appliance maker Oventus Medical Ltd has launched its first five “lab in lab” sites in the United States and Canada to coincide with the launch of the O2Vent Optima oral device within US sleep and dental channels. In September, the O2Vent Optima received regulatory clearance from the FDA.
“Since we announced our first Canadian agreements in June and US agreements in July, our team has worked with a number of clinical delivery sites to implement our ‘lab in lab’ model. Bookings are now being taken across the first 5 sites,” says Oventus CEO and managing director, Chris Hart, MPhil, BSc, BDSc. “The current time from signing an agreement to a site taking patient bookings is about 60 days. Once bookings can be taken, first booked revenue is expected within 60 days and ramp time to minimum quotas can be up to 90 days. This means sales will increase in the December quarter while sales in the September quarter will be roughly in line with previous quarters. We are actively investing funds from our recent capital raising into resources that will support the growth of the ‘lab in lab’ program and to streamline the implementation process. We expect this will reduce lead times to revenue. This is particularly important given growing demand for both Oventus’ clinical delivery model and our O2Vent Optima treatment for obstructive sleep apnea (OSA).”

At the same time, the Oventus marketing team has launched a digital marketing and outreach campaign  to communicate the availability of the O2Vent Optima in the United States. Targeting sleep and dental channels, the campaign is designed to alert those clinicians waiting for Optima clearance to the fact that it is now available.

The O2Vent Optima is the newest product in the O2Vent oral device range within Oventus’ Sleep Treatment Platform. It is a customized 3D-printed nylon oral appliance that offers mandibular advancement device, as well as a separate airway that adds further stability to the upper airway for OSA patients throughout the night.

An already growing pipeline of potential agreements is being supported by the official launch of the O2Vent Optima. Oventus expects to secure and announce further agreements across its key markets over the next 12-24 months.